Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial-Reference-Cited by-同舟云学术

Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial

Published:2019-12 Issue:5 Volume:105 Page:943-947
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Olson Robert,Senan Suresh,Harrow Stephen,Gaede Stewart,Louie Alexander,Haasbeek Cornelis,Mulroy Liam,Lock Michael,Rodrigues George,Yaremko Brian,Schellenberg Devin,Ahmad Belal,Griffioen Gwendolyn,Senthi Sashendra,Swaminath Anand,Kopek Neil,Liu Mitchell,Moore Karen,Currie Suzanne,Bauman Glenn,Warner Andrew,Palma David

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference22 articles.

1. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

2. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after front-line systemic therapy: A multicenter, randomized, controlled, phase 2 study;Gomez;Lancet Oncol,2016

3. SABR-COMET: Harbinger of a new cancer treatment paradigm;Loo;Lancet,2019

4. Assessment of quality-of-life outcomes;Testa;N Engl J Med,1996

5. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial;Velikova;J Clin Oncol,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial;International Journal of Radiation Oncology*Biology*Physics;2024-08

2. Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours;Journal of Clinical Medicine;2024-05-21

3. Predictive value of magnetic resonance imaging diffusion parameters using artificial intelligence in low-and intermediate-risk prostate cancer patients treated with stereotactic ablative radiotherapy: A pilot study;Radiography;2024-05

4. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial;Clinical Oncology;2024-03